Paradoxical response with increased tumor necrosis factor-α levels to anti-tuberculosis treatment in a patient with disseminated tuberculosis

@inproceedings{Watanabe2017ParadoxicalRW,
  title={Paradoxical response with increased tumor necrosis factor-α levels to anti-tuberculosis treatment in a patient with disseminated tuberculosis},
  author={Sho Watanabe and Yugo Kaneko and Hironori Kawamoto and Tomoki Maehara and Yuri Baba and Ikumi Fujisaki and Nayuta Saito and Kai Ryu and Aya Seki and Tsugumi Horikiri and Akira Kinoshita and Hiroshi Takeda and Keisuke Saito and Kazuyosi Kuwano},
  booktitle={Respiratory medicine case reports},
  year={2017}
}
It has been reported that tuberculosis (TB) worsens after cessation of tumor necrosis factor-α inhibitors and starting anti-TB treatment. Little is known about the immunological pathogenesis of this paradoxical response (PR). We report the first case of a TB patient in whom PR occurred concurrently with elevation of circulating tumor necrosis factor-α (TNFα) levels. A 75-year-old woman, who had been treated with adalimumab for SAPHO syndrome, developed disseminated TB. Soon after administration… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 12 REFERENCES

Adalimumab treatment of life-threatening tuberculosis.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2009
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Sch€ olvinck

I. Solovic, M. Sester, +9 authors E.H.G. Sotgiu
  • Eur. Respir. J
  • 2010
VIEW 1 EXCERPT

Tumour necrosis factor antagonists: structure, function, and tuberculosis

R. S. Wallis
  • risks, Lancet Infect. Dis
  • 2008
VIEW 1 EXCERPT

Use of the QuantiFERON-TB Gold In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis.

  • The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
  • 2008
VIEW 1 EXCERPT